Dendritic cells enhance tebentafusp-mediated T cell effector responses
Tebentafusp is the first approved T cell receptor (TCR)-based bispecific therapy and prolongs survival in metastatic uveal melanoma by redirecting T cells against gp100/HLA-A*02:01-positive tumor cells. However, how tebentafusp reshapes immune-cell interactions within the tumor microenvironment remains incompletely understood. Here, using HLA-defined donor T cells, dendritic cells (DCs), and tumor cell models with distinct gp100 and HLA-A*02:01 expression profiles, we identify a DC-dependent mechanism that enhances tebentafusp-mediated T cell activation, cytokine production, and cytotoxicity. Across the tumor cell models, the magnitude of tebentafusp-mediated functional responses was closely associated with gp100 abundance and HLA-A*02:01 surface expression. This DC-dependent enhancement was not explained by conventional antigen presentation or the tested CD80/CD86 pathway and was not further enhanced by PD-1 or CTLA-4 blockade. Notably, following direct co-culture with gp100-positive, HLA-A*02:01-positive tumor cells, HLA-A*02:01-negative DCs displayed surface-bound tebentafusp and subsequently enabled tebentafusp-specific T cell activation despite the HLA mismatch. Transfer required gp100 and HLA-A*02:01 expression as well as direct cell–cell contact, consistent with functional DC cross-dressing. Together, these findings reveal a DC-mediated amplification mechanism that extends tebentafusp activity beyond direct tumor–T cell interactions and may shape immune redirection within the tumor microenvironment.
Authors
- Kilian Schober (ORCID: https://orcid.org/0000-0001-9323-9472)
- Markus Luber (ORCID: https://orcid.org/0000-0003-1895-5481)
- Elias A. T. Koch (ORCID: https://orcid.org/0000-0003-2005-7533)
- Anne Petzold (ORCID: https://orcid.org/0000-0003-3558-9014)
- Manuel Wiesinger (ORCID: https://orcid.org/0009-0005-3947-4355)
- Beatrice Schuler‐Thurner (ORCID: https://orcid.org/0000-0001-8653-5425)
- Markus Vincent Heppt (ORCID: https://orcid.org/0000-0003-4603-1825)
- Philipp Hilgendorf (ORCID: https://orcid.org/0009-0008-0673-1898)
- Carola Berking
- Andreas Wild
Institutions
- Friedrich-Alexander-Universität Erlangen-Nürnberg (DE)
- Universitätsklinikum Erlangen (DE)
- Comprehensive Cancer Center Erlangen (DE)
Publication Details
- Journal
- Cancer Immunology Immunotherapy
- Published
- 2026-11-14
- DOI
- https://doi.org/10.1007/s00262-026-04609-3
- Primary Topic
- Immunotherapy and Immune Responses
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Universitätsklinikum Erlangen